MET and neoplasm: Inhibition of certain receptor tyrosine kinases (cMET, VEGFR2, RET, KIT, AXl, and FLT3) using a promiscuous small molecule inhibitor, cabozantinib, has also led to higher neutrophil infiltration into the tumor.